Advertisement
Advertisement
U.S. Markets close in 24 mins
Advertisement
Advertisement
Advertisement
Advertisement

Axcella Health Inc. (AXLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.5500+0.1600 (+6.69%)
As of 03:32PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3900
Open2.3700
Bid2.5200 x 900
Ask2.5400 x 3000
Day's Range2.3500 - 2.5500
52 Week Range1.3500 - 4.4000
Volume38,990
Avg. Volume65,948
Market Cap99.237M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Axcella Reports Second Quarter Financial Results and Provides Business Update

    CAMBRIDGE, Mass., August 12, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

  • Business Wire

    Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

    CAMBRIDGE, Mass., August 02, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.

  • Business Wire

    Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

    CAMBRIDGE, Mass., May 26, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID. The company affirmed topline data readout for its Phase 2a Long COVID trial in early Q3 2022 and interim data readout for N

Advertisement
Advertisement